About this trial
Objective: To develop and validate a predictive model for acquiring sexually transmitted infections (STIs) in individuals using HIV pre-exposure prophylaxis (PrEP) within the national program providing this strategy.
Methods: Ambispective cohort study, multicentric (23 Spanish hospitals). All PrEP users, with follow-up within the program, will be included. Entry into the program will be considered as the baseline visit. From there, patients are followed quarterly, following the national protocols for monitoring PrEP users in Spain. At each visit, diagnosis of different STIs (serum, pharyngeal swab, urethral or urine sample, rectal swab, endocervical/vaginal swab, ulcer) is performed. Primary outcome variable: development of an STI (Yes/No). The following STIs will be considered: syphilis, Neisseria gonorrhoeae (NG) infection, Chlamydia trachomatis (CT) infection, lymphogranuloma venereum (LGV), Mycoplasma genitalium (MG) infection, genital herpes, hepatitis A, hepatitis B, hepatitis C, HIV infection, and MPOX. Secondary outcome variable: number of diagnosed STIs. In order to determine factors associated with acquiring an STI, multivariate analyses will be conducted using logistic regression. The best models will be analyzed in the validation population. To compare the models, we will follow the Bayesian approach suggested by Benavoli et al.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
All individuals with documented initiation of oral PrEP (daily or event-driven regimens), who have collected the medication at least once and have taken at least one pill, will be included in the study.
People without HIV infection at the time of cohort inclusion
MSM and transgender women with at least two of the following criteria during the last year: > 10 sexual partners; Condomless anal sex; Chemsex; PEP; ≥ 1 STI
Sex worker women who report non-habitual use of condoms.
Disqualifiers
None
Trial population
All individuals who meet the criteria for PrEP use in Spain, are over 16 years old, and have taken at least one pill.
Trial design
Cohort
Other
Treatments tested in this trial
No Intervention: Observational Cohort
Other interventionNo Intervention: Observational Cohort
Treatment groups
Trial outcomes
Primary outcomes
STI predictive model
Predictive model for the acquisition of sexually transmitted infections in individuals using PrEP within the national provision program for this strategy
Secondary outcomes
STI incidence
Incidence of sexually transmitted infections (STIs) in the cohort globally and by type of infection.
STI dynamics
Evolution of STI diagnoses during follow-up among PrEP users included in the study, both globally and by specific pathogen
asymptomatic STIs
Proportion of asymptomatic STIs diagnosed within the screening program.
behavioral changes
Sexual risk behaviors of individuals in the cohort, before and after initiating PrEP
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Hospital Universitario de Valme
Lead sponsor
Hospital Clínico Universitario de Valencia
Sponsor institution
Instituto de Salud Carlos III
Collaborator